We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The United Nations High-Level Panel on Access to Medicine is proposing that governments rely on compulsory licenses to improve patient access to medicines in a highly anticipated report that has been met with dismay from industry. Read More
Eisai presented data from two Phase III studies of adjunctive therapies for epilepsy—one evaluating the non-inferiority of Zebinix compared to carbamazepine, and an open-label extension study of long-term Fycompa, which demonstrated sustained seizure control for up to two-and-a-half years. The two studies were presented at the European Congress on Epileptology. Read More
Novo Nordisk presented two separate Phase III studies in type 2 diabetes—evaluating semaglutide and Xultophy—at the annual meeting of the European Association for the Study of Diabetes. Read More
Plasma fibrinogen can be used as a biomarker in interventional clinical trials examining patients at high risk for exacerbations or all-cause mortality in chronic obstructive pulmonary disease, according to final guidance to industry issued by FDA. Read More